IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent Application of Fabrizio SAMARITANI et al. Serial No.: 08/737,633
Filed: November 15, 1996



Date: December 17, 1999

Group Art Unit: 1646

Examiner: D. Fitzgerald

For: IFN-BETA LIQUID FORMULATIONS

AMENDMENT TRANSMITTAL LETTER - FEE COMPUTATION

Assistant Commissioner for Patents

Washington, D.C. 20231

Transmitted herewith is an amendment in the above-identified application.

____"Small Entity" status (37 C.F.R. §1.9 & §1.27) established

previously by enclosed verified statement.

OFGS Check No. _____, which includes the fee of <u>-0-</u> calculated below, is attached.

NO. CLAIMS			HIGHEST NO.						
AFTER			PREVIOUSLY						ADDIT.
AMENDMENT			PAID FOR	EX	TRA PRES	ENT	RATE	RATE FEE	
TOTAL	9	MINUS	20	* =	0	X	(\$9 SE or \$18)	\$	0.00
INDEP.	1	MINUS	3	**=	0	X	(\$39 SE or \$78)	\$_	0.00
FIRST PRE	SENT	ATION OF	MULTIPLE DEP	ENDENT	CLAIM	X	(\$130 SE or \$260)	\$	0.00
* not less that	an 20	**	not less than 3				TOTAL	\$_	0.00

In the event the actual fee is greater than the payment submitted or is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 15-0700.

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. §1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 C.F.R. §1.135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 15-0700.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on December 17, 1999:

Charles C. Achkar
Name of applicant, assignee or
Registered Representative

December 17, 1999

Date of Signature

EAM/CCA:lac

Respectfully submitted,

Charles C. Achkar

Registration No.: 43,311

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas New York, New York 10036-8403

Telephone: (212) 382-0700





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Date: December 17, 1999

Examiner: D. Fitzgerald

Group Art Unit: 1646

In re: Patent Application of

Fabrizio SAMARITANI et al.

Serial No.: 08/737,633

Filed: November 15, 1996

For: IFN-BETA LIQUID FORMULATIONS

Assistant Commissioner for Patents

Washington, D.C. 20231

AMENDMENT IN REPLY TO JULY 2, 1999 OFFICE ACTION

Sir:

In reply to the Office Action dated July 2, 1999, please reconsider the above-identified application in view of the following amendments and remarks.

IN THE CLAIMS:

Please amend claims 1 and 9 as follows:

est 17

--1. (Three Times Amended) A [stable,] liquid pharmaceutical formulation consisting of from about 0.6 to 24 MIU/ml of interferon-beta, [a stabilizing amount of] mannitol, a buffer [capable of maintaining the] at a pH [of the formulation at a value] between 3.0 and 4.0 and, optionally, albumin.--

EN 73/

--9. (Amended) [Process] <u>A process</u> for the preparation of a [liquid] pharmaceutical formulation according to claim 1, comprising [the dilution of] <u>combining</u> interferon-beta with [a solution of excipients] <u>mannitol</u>, a <u>buffer</u> at <u>pH</u> between 3.0 and 4.0 and, optionally, albumin.--